体内评价赖氨酸特异性去甲基酶（KDM1A/LSD1）抑制剂 SP-2577（塞克西达美司他）针对儿科肉瘤临床前模型的疗效：来自儿科临床前测试联盟（PPTC）的报告。
In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).
机构信息
Greehey Children's Cancer Research Institute, San Antonio, Texas, USA.
RTI International, Research Triangle Park, North Carolina, USA.
出版信息
Pediatr Blood Cancer. 2021 Nov;68(11):e29304. doi: 10.1002/pbc.29304. Epub 2021 Aug 28.
Abstract
SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed in pediatric sarcomas, was evaluated against pediatric sarcoma xenografts. SP-2577 (100 mg/kg/day × 28 days) statistically significantly (p < .05) inhibited growth of three of eight Ewing sarcoma (EwS), four of five rhabdomyosarcoma (RMS), and four of six osteosarcoma (OS) xenografts. The increase in EFS T/C was modest (<1.5) for all models except RMS Rh10 (EFS T/C = 2.8). There were no tumor regressions or consistent changes in dimethyl histone H3(K4), HOXM1, DAX1, c-MYC and N-MYC, or tumor histology/differentiation. SP-2577 has limited activity against these pediatric sarcoma models at the dose and schedule evaluated.
摘要
SP-2577（塞克西得美司他）是一种组蛋白赖氨酸特异性去甲基化酶 KDM1A（LSD1）抑制剂，在儿科肉瘤中过表达，针对儿科肉瘤异种移植进行了评估。SP-2577（100mg/kg/天×28 天）在统计学上显著（p<0.05）抑制了 8 种尤文肉瘤（EwS）中的 3 种、5 种横纹肌肉瘤（RMS）中的 4 种和 6 种骨肉瘤（OS）异种移植的生长。除 RMS Rh10（EFS T/C=2.8）外，所有模型的 EFS T/C 增加均适中（<1.5）。没有肿瘤消退或组蛋白 H3（K4）二甲基化、HOXM1、DAX1、c-MYC 和 N-MYC 的一致变化，或肿瘤组织学/分化。在评估的剂量和方案下，SP-2577 对这些儿科肉瘤模型的活性有限。
相似文献
1
In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).
Pediatr Blood Cancer. 2021 Nov;68(11):e29304. doi: 10.1002/pbc.29304. Epub 2021 Aug 28.
2
Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Mol Cancer Ther. 2018 Sep;17(9):1902-1916. doi: 10.1158/1535-7163.MCT-18-0373. Epub 2018 Jul 11.
3
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Hum Pathol. 2012 Aug;43(8):1300-7. doi: 10.1016/j.humpath.2011.10.010. Epub 2012 Jan 13.
4
Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
Pediatr Blood Cancer. 2019 Sep;66(9):e27888. doi: 10.1002/pbc.27888. Epub 2019 Jun 17.
5
Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Clin Cancer Res. 2014 Sep 1;20(17):4584-97. doi: 10.1158/1078-0432.CCR-14-0072. Epub 2014 Jun 24.
6
Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
Pediatr Blood Cancer. 2010 Dec 1;55(6):1224-6. doi: 10.1002/pbc.22355.
7
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Oncotarget. 2016 Apr 5;7(14):17616-30. doi: 10.18632/oncotarget.7124.
8
Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
J Med Chem. 2021 Mar 11;64(5):2466-2488. doi: 10.1021/acs.jmedchem.0c02176. Epub 2021 Feb 23.
9
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Cancer Res. 2009 Oct 1;69(19):7662-71. doi: 10.1158/0008-5472.CAN-09-1693. Epub 2009 Sep 29.
10
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40. doi: 10.1007/s00280-008-0922-4. Epub 2009 Feb 18.
引用本文的文献
1
Synthetic and structure-activity studies of SP2577 and TCP towards LSD1 targeting PROTACs.
RSC Med Chem. 2025 Aug 5. doi: 10.1039/d5md00420a.
2
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids.
Res Sq. 2025 May 15:rs.3.rs-6602839. doi: 10.21203/rs.3.rs-6602839/v1.
3
Discovery of highly potent and novel LSD1 inhibitors for the treatment of acute myeloid leukemia: structure-based virtual screening, molecular dynamics simulation, and biological evaluation.
Front Pharmacol. 2025 Feb 27;16:1510319. doi: 10.3389/fphar.2025.1510319. eCollection 2025.
4
Collaborative Innovations in Childhood Cancer Therapies.
Handb Exp Pharmacol. 2024;286:33-50. doi: 10.1007/164_2024_725.
5
Unlocking epigenetics for precision treatment of Ewing's sarcoma.
Chin J Cancer Res. 2024 Jun 30;36(3):322-340. doi: 10.21147/j.issn.1000-9604.2024.03.08.
6
Anticancer Drugs of Lysine Specific Histone Demethylase-1 (LSD1) Display Variable Inhibition on Nucleosome Substrates.
Biochemistry. 2024 Jun 4;63(11):1369-1375. doi: 10.1021/acs.biochem.4c00090. Epub 2024 May 14.
7
Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors.
Mol Divers. 2024 Dec;28(6):4403-4424. doi: 10.1007/s11030-024-10824-w. Epub 2024 Mar 24.
8
Current Approaches to Epigenetic Therapy.
Epigenomes. 2023 Sep 30;7(4):23. doi: 10.3390/epigenomes7040023.
9
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Int J Mol Sci. 2023 Jul 12;24(14):11367. doi: 10.3390/ijms241411367.
10
Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma.
Front Oncol. 2023 Jan 4;12:1076581. doi: 10.3389/fonc.2022.1076581. eCollection 2022.
本文引用的文献
1
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.
Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. doi: 10.1016/j.celrep.2019.09.071.
2
Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Clin Cancer Res. 2014 Sep 1;20(17):4584-97. doi: 10.1158/1078-0432.CCR-14-0072. Epub 2014 Jun 24.
3
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.
Clin Cancer Res. 2013 Dec 15;19(24):6716-29. doi: 10.1158/1078-0432.CCR-13-0842. Epub 2013 Oct 16.
4
Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Oncogene. 2013 Oct 17;32(42):5089-100. doi: 10.1038/onc.2012.525. Epub 2012 Nov 26.
5
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Hum Pathol. 2012 Aug;43(8):1300-7. doi: 10.1016/j.humpath.2011.10.010. Epub 2012 Jan 13.
6
Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis.
Epigenomics. 2011 Dec;3(6):715-32. doi: 10.2217/epi.11.93.
7
LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells.
Nat Cell Biol. 2011 Jun;13(6):652-9. doi: 10.1038/ncb2246. Epub 2011 May 22.
8
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Hum Pathol. 2011 Nov;42(11):1667-75. doi: 10.1016/j.humpath.2010.12.025. Epub 2011 Apr 29.
9
Histone demethylase LSD1 is required to induce skeletal muscle differentiation by regulating myogenic factors.
Biochem Biophys Res Commun. 2010 Oct 22;401(3):327-32. doi: 10.1016/j.bbrc.2010.09.014. Epub 2010 Sep 15.
10
Conversion of mouse epiblast stem cells to an earlier pluripotency state by small molecules.
J Biol Chem. 2010 Sep 24;285(39):29676-80. doi: 10.1074/jbc.C110.150599. Epub 2010 Aug 12.
Zotero 插件